Vera Therapeutics Inc Cl A VERA

$30.42 -0.57 (-1.84%)

Valuation

Market cap
2,233,233,000
Revenue TTM
$0
Net income TTM
$-299,610,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.18

Trading

Volume
1,614,800
Avg volume
2,234,832
Day's range
$29.80 – $31.27
Shares out
72,063,000
Stochastic %K
9%
Beta
1.06
Analysts
Strong Sell
Price target
$74.73

Price

Company profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluat...

Show more

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 770 0077
Website
https://veratx.com
Address
2000 Sierra Point Parkway, Suite 1200, Brisbane, United States

Latest news

Stocktwits

dgbio Oct 2, 7:42 PM
$VERA Reading Kidney Week abstracts: "Sibeprenlimab ranked highest for proteinuria reduction and co-ranked with Atacicept for eGFR preservation; Atacicept was the only agent with significantly lower SAE hazard versus all treatments. No treatment differed significantly from SOC for IEs. These findings highlight the need for direct head-to-head RCTs to confirm the comparative efficacy and safety profiles suggested by indirect network estimates". From Comparative Efficacy and Safety of IgAN Treatments: A Bayesian Network Meta-Analysis https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4553582
0 replies
CH_Expat Oct 2, 6:15 PM
$VERA Watching here. Short the launch games. Can end soon, can go on for a very long time.
0 replies
Theflash88 Oct 2, 4:02 PM
$VERA Time to buy. Also Check out $QGEN
0 replies
TKkamen Oct 2, 3:34 PM
$VERA Why on earth are we down 4%.
0 replies
yesitrade Oct 2, 2:33 PM
$VERA Added again; 30.21
0 replies
flamingojack Oct 2, 1:28 PM
$VERA
0 replies
DARKP00L Oct 2, 1:27 PM
$VERA Vera therapeutics announces origin 3 final efficacy analysis of trutakna™ (atacicept-vymj) in iga nephropathy will be a featured late-breaking oral presentation at the opening plenary session of asn kidney week 2026
0 replies
flamingojack Oct 1, 9:03 PM
$VERA all kidney drug makers took a hit today. We didn’t even get the worst of it.
0 replies